Dhindsa, Ryan S. http://orcid.org/0000-0002-8965-0813
Mattsson, Johan
Nag, Abhishek
Wang, Quanli
Wain, Louise V. http://orcid.org/0000-0003-4951-1867
Allen, Richard http://orcid.org/0000-0002-8450-3056
Wigmore, Eleanor M.
Ibanez, Kristina
Vitsios, Dimitrios
Deevi, Sri V. V. http://orcid.org/0000-0002-0405-4335
Wasilewski, Sebastian
Karlsson, Maria
Lassi, Glenda
Olsson, Henric
Muthas, Daniel
Monkley, Susan
Mackay, Alex
Murray, Lynne
Young, Simon
Haefliger, Carolina http://orcid.org/0000-0002-5095-5716
Maher, Toby M. http://orcid.org/0000-0001-7192-9149
Belvisi, Maria G. http://orcid.org/0000-0003-1652-4370
Jenkins, Gisli http://orcid.org/0000-0002-7929-2119
Molyneaux, Philip L. http://orcid.org/0000-0003-1301-8800
Platt, Adam http://orcid.org/0000-0002-3455-1789
Petrovski, Slavé
,
Article History
Received: 10 September 2020
Accepted: 24 February 2021
First Online: 23 March 2021
Competing interests
: R.S.D., J.M., A.N., Q.W., E.M.W., D.V., S.V.V.D., S.W., M.K., G.L., H.O., D.M., S.M., A.M., C.H., M.G.B., A.P., and S.P. are current employees and/or stockholders of AstraZenca. G.J. reports personal fees and other from Biogen, personal fees from Galapagos, other from Galecto, personal fees and other from GlaxoSmithKline, personal fees from Heptares, personal fees from Boehringer Ingelheim, personal fees from Pliant, personal fees from Roche/InterMune, personal fees from MedImmune, personal fees from PharmAkea, personal fees from Bristol Myers Squibb, personal fees from Chiesi, personal fees from Roche/Promedior, other from RedX, other from NuMedii, other from Nordic Biosciences, personal fees from Veracyte, outside the submitted work; and G.J. is supported by a National Institute of Health Research Professorship (NIHR ref: RP-2017-08-ST2-014) and is a trustee for Action for Pulmonary Fibrosis. P.L.M. via his institution received industry-academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche outside the submitted work. L.V.W. has received grant funding from GSK and Orion outside of the submitted work. T.M.M. has via his institution, received industry-academic funding from Astra Zeneca and GlaxoSmithKline R&D and has received consultancy or speakers fees from Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline R&D, IQVIA, Pliant, Respivant, Roche and Theravance. The remaining authors declare no competing interests.